Commentary on 'Payment in challenge studies: ethics, attitudes and a new payment for risk model'

Grimwade et al highlight the current lack of a universal, standardised approach to the payment of participants taking part in controlled human infection model (CHIM) studies.1 As they discuss, payment for these studies is controversial, with many voicing arguments for and against higher payments, pa...

Full description

Saved in:  
Bibliographic Details
Main Author: Payne, Ruth (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 2020
In: Journal of medical ethics
Year: 2020, Volume: 46, Issue: 12, Pages: 829-830
Online Access: Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000caa a22000002 4500
001 1816163937
003 DE-627
005 20230428063545.0
007 cr uuu---uuuuu
008 220908s2020 xx |||||o 00| ||eng c
024 7 |a 10.1136/medethics-2020-106975  |2 doi 
035 |a (DE-627)1816163937 
035 |a (DE-599)KXP1816163937 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Payne, Ruth  |e VerfasserIn  |4 aut 
245 1 0 |a Commentary on 'Payment in challenge studies: ethics, attitudes and a new payment for risk model' 
264 1 |c 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Grimwade et al highlight the current lack of a universal, standardised approach to the payment of participants taking part in controlled human infection model (CHIM) studies.1 As they discuss, payment for these studies is controversial, with many voicing arguments for and against higher payments, particularly for those studies which involve significant burdens to the participant. The main concerns about overpayment relate to the concepts of undue inducement or coercion, whereas underpayment raises concern about exploitation and unfair treatment. In many healthy volunteer trials compensation for travel, time and inconvenience are generally accepted as fair payment, but payment for risk is less accepted, with a belief that non-therapeutic studies should only incur minimal risks, so payment for risk should not be necessary.2 This paper argues that payment for risk should be included for CHIM studies. Their findings among members of the UK public and CHIM experts from a variety of centres suggest that there is support for greater risks being associated with higher payments for participants. The amount of compensation offered by a trial has to be approved by an ethics committee/institutional review board (IRB), and some research suggests that IRB members have concerns about higher payments being offered, with only approximately one-third agreeing that payment should be offered for risk.3 Without agreement and clear guidance for calculating compensation for these types of trial, there is bound to be … 
601 |a Challenger 
773 0 8 |i Enthalten in  |t Journal of medical ethics  |d London : BMJ Publ., 1975  |g 46(2020), 12, Seite 829-830  |h Online-Ressource  |w (DE-627)323607802  |w (DE-600)2026397-1  |w (DE-576)260773972  |x 1473-4257  |7 nnns 
773 1 8 |g volume:46  |g year:2020  |g number:12  |g pages:829-830 
856 4 0 |u https://doi.org/10.1136/medethics-2020-106975  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://jme.bmj.com/content/46/12/829.abstract  |x Verlag  |z lizenzpflichtig  |3 Volltext 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4185617879 
LOK |0 003 DE-627 
LOK |0 004 1816163937 
LOK |0 005 20220908053756 
LOK |0 008 220908||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-08-03#222B94DD2B03E042B23288FEA3DDCFF3027801B0 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1  |b inherited from superior work 
ORI |a SA-MARC-ixtheoa001.raw